$10,178 Mln
$728 Mln
14.14
As on 29-Sep-2023 16:00 EDT
$-0.16
•
-0.07%
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
United Therapeutics (UTHR)
| -18.78 | -2.42 | 5.15 | 7.01 | 30.55 | 12.05 | 11.12 |
|
S&P BSE Sensex
| 8.20 | 1.28 | 2.99 | 16.31 | 20.12 | 12.69 | 12.81 |
|
#
| -- | -- | -- | -- | -- | -- | -- |
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
|
|---|---|---|---|---|---|---|---|
|
United Therapeutics (UTHR)
| 28.70 | 42.35 | 72.33 | -19.12 | -26.27 | 3.15 | -8.42 |
|
S&P BSE Sensex
| 4.44 | 21.99 | 15.75 | 14.38 | 5.87 | 27.91 | 1.95 |
|
S&P BSE Sensex
| 4.44 | 21.99 | 15.75 | 14.38 | 5.87 | 27.91 | 1.95 |
|
Stock
|
Peer Median
|
||
|---|---|---|---|
Please wait... |
|||
|
Stock
|
Peer Median
|
||
|---|---|---|---|
Please wait... |
|||
The total asset value of United Therapeutics Corporation (UTHR) stood at $ 6,671 Mln as on 31-Mar-23
The share price of United Therapeutics Corporation (UTHR) is $225.870000 (NASDAQ) as of 29-Sep-2023 16:00 EDT. United Therapeutics Corporation (UTHR) has given a return of 30.55% in the last 3 years.
United Therapeutics Corporation (UTHR) has a market capitalisation of $ 10,178 Mln as on 02-Jun-2023. As per Value Research classification, it is a company.
The P/B ratio of United Therapeutics Corporation (UTHR) is 2.80 times as on 02-Jun-2023, a 0.1% premium to its peers’ median range of 2.54 times.
The P/E (price to earnings) ratio of United Therapeutics Corporation (UTHR) is 14.14 times as on 02-Jun-2023.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the United Therapeutics Corporation (UTHR) and enter the required number of quantities and click on buy to purchase the shares of United Therapeutics Corporation (UTHR).
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled solution via ultrasonic nebulizer; Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Remunity Pump, a small, lightweight, durable pump and separate controller; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and TETON studies, which are the studies of Tyvaso for the treatment of idiopathic pulmonary fibrosis. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
The CEO & director of Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D.. is United Therapeutics Corporation (UTHR), and CFO & Sr. VP is Mr. Michael I. Benkowitz.
The promoters of United Therapeutics Corporation (UTHR) have pledged 0% of the total equity as on Mar-23.
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
313
|
|
|
286
|
|
|
34
|
|
|
10
|
| United Therapeutics Corporation (UTHR) | Ratios |
|---|---|
|
Return on equity(%)
|
15.04
|
|
Return on capital employed(%)
|
--
|
|
Debt-to-equity ratio
|
0.16
|
|
Dividend yield(%)
|
0
|
Yes, TTM profit after tax of United Therapeutics Corporation (UTHR) was $728 Mln.
$10,177.73 Mln
$1,981.30 Mln
$728.30 Mln
$2,863.40 Mln
$800.00 Mln
High
$204.44 - 283.09
46,854,500
NASDAQ: UTHR
Silver Spring, MD
https://www.unither.com
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally.... Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled solution via ultrasonic nebulizer; Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Remunity Pump, a small, lightweight, durable pump and separate controller; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and TETON studies, which are the studies of Tyvaso for the treatment of idiopathic pulmonary fibrosis. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland. Read more
Learn the principles, mindset and tools you need to become a successful Mutual Fund and Stock investor from the masters who have been doing this for decades.
Use India's most advanced investment tracker to track, analyse and get updates and insights on your investments.
Get an analysis of your portfolio along with actionable, general tips and insights, guidance on where to invest based on your goals, and experts' opinions on individual Mutual Funds and Stocks.
Value Research offers the most advanced and detailed data & analytics available on Mutual Funds and Stocks. Sign up and unlock the power yourself.
Unlimited access to advice from India's top experts
The most comprehensive analysis of funds and stocks in India
A holistic portfolio manager to help track all your investments easily
And much more, like guides, tools, webinars, videos and eBooks.
Share via Facebook 
Share via Twitter 
Share via LinkedIn 
Share this
